Market Overview

UPDATE: UBS Securities Upgrades Allergan On Conference Call Takeaways

Related AGN
Barron's Picks And Pans: Super Chip Stocks, Time Warner And More
Kevin Kelly's Allergan Trade
Gilead NASH Drug 'Active And Promising,' But Lagging Intercept (Investor's Business Daily)

In a report published Tuesday, UBS Securities analyst Marc Goodman upgraded the rating on Allergan (NYSE: AGN) from Neutral to Buy, and raised the price target from $180.00 to $200.00.

In the report, UBS Securities noted, “Investors have been waiting for 2 Allergan events: a restructuring and an accretive deal. Given the Friday PR for the conf call today, many investors were expecting a deal to be announced today and thus were disappointed from that perspective. But the cost cutting was solid and viewed positively (on top of the very strong qtr), and mgt couldn't have been more confident that it can get a deal done in time. Now we wait for this deal. Can Allergan create close to as much ST value as Valeant can with its cost cuts?”

Allergan closed on Monday at $171.14.

Latest Ratings for AGN

Aug 2016MizuhoUpgradesNeutralBuy
Aug 2016Deutsche BankMaintainsBuy
Jul 2016Credit SuisseInitiates Coverage onOutperform

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Marc Goodman UBS SecuritiesAnalyst Color Upgrades Analyst Ratings


Related Articles (AGN)

View Comments and Join the Discussion!